F-Prime backs a niche AI soft­ware start­up hunt­ing lofty goals in $22M Se­ries B

For many of the AI com­pa­nies sprout­ing on the bio­phar­ma field, val­i­da­tion — of­ten mean­ing con­fir­ma­tion of whether the tar­gets and drugs they iden­ti­fied or gen­er­at­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER